Claims
- 1. As a composition of matter, a liposome comprising:
adenoviral DNA, wherein the adenoviral DNA comprises a circular form; and a therapeutic polynucleotide.
- 2. The composition of claim 1, wherein the adenoviral DNA comprises the therapeutic polynucleotide.
- 3. The composition of claim 1, wherein the adenoviral DNA is contained within the liposome.
- 4. The composition of claim 1, wherein the adenoviral DNA is housed within an adenoviral particle.
- 5. The composition of claim 1, wherein the adenoviral DNA is native adenoviral DNA.
- 6. The composition of claim 1, wherein the adenoviral DNA is recombinant.
- 7. The composition of claim 1, wherein the adenoviral DNA is replication-deficient.
- 8. The composition of claim 1, wherein the adenoviral DNA is dl1520.
- 9. The composition of claim 1, wherein the liposome is a bilammelar liposome.
- 10. The composition of claim 1, wherein the liposome is comprised of DOTAP.
- 11. The composition of claim 1, wherein the liposome is comprised of extruded DOTAP-cholesterol.
- 12. The composition of claim 1, wherein said composition further comprises humoral immune response-neutralizing activity.
- 13. A therapeutic composition, comprising:
a liposome, comprising:
adenoviral DNA, wherein the adenoviral DNA comprises a circular form; and a therapeutic polynucleotide; and a pharmaceutical carrier.
- 14. The composition of claim 13, wherein the adenoviral DNA comprises the therapeutic polynucleotide.
- 15. The composition of claim 13, wherein the adenoviral DNA is contained within the liposome.
- 16. The composition of claim 13, wherein the adenoviral DNA is native adenoviral DNA.
- 17. The composition of claim 13, wherein the adenoviral DNA is recombinant.
- 18. The composition of claim 13, wherein the adenoviral DNA is replication-deficient.
- 19. The composition of claim 13, wherein the adenoviral DNA is dl1520.
- 20. The composition of claim 13, wherein the liposome is a bilammelar liposome.
- 21. The composition of claim 13, wherein the liposome is comprised of DOTAP.
- 22. The composition of claim 13, wherein the liposome is comprised of extruded DOTAP-cholesterol.
- 23. The composition of claim 13, wherein said composition further comprises humoral immune response-neutralizing activity.
- 24. A vaccine comprising the composition of claim 13.
- 25. A method of treating a disease in an individual comprising the step of administering to the individual a composition comprising a liposome, said liposome comprising:
adenoviral DNA, wherein the adenoviral DNA comprises a circular form; a therapeutic polynucleotide; and a pharmaceutical carrier.
- 26. The method of claim 25, wherein the adenoviral DNA comprises the therapeutic polynucleotide.
- 27. The method of claim 25, wherein the adenoviral DNA is contained within the liposome.
- 28. The method of claim 25, wherein the composition is administered at least a second time.
- 29. The method of claim 25, wherein the individual is a warm-blooded animal.
- 30. The method of claim 29, wherein the animal is a human.
- 31. The method of claim 25, wherein the disease is cancer.
- 32. The method of claim 31, wherein the cancer is lung cancer.
- 33. The method of claim 25, wherein the therapeutic polynucleotide encodes p53, BRCA1, BRCA2, a bone morphogenetic protein, an interleukin, thymidine kinase, or cytosine deaminase.
- 34. The method of claim 25, wherein the adenoviral DNA is dl1520.
- 35. The method of claim 25, wherein the liposome is a bilammelar liposome.
- 36. The method of claim 25, wherein the liposome is comprised of DOTAP.
- 37. The method of claim 25, wherein the liposome is comprised of extruded DOTAP-cholesterol.
- 38. The method of claim 25, wherein said composition further comprises humoral immune response-neutralizing activity.
- 39. A method of preventing a disease in an individual comprising the step of administering to the individual a composition comprising a liposome, said liposome comprising:
adenoviral DNA, wherein the adenoviral DNA comprises a circular form; a therapeutic polynucleotide; and a pharmaceutical carrier.
- 40. The method of claim 39, wherein the composition is administered at least a second time.
- 41. As a composition of matter, a liposome comprising within a circular adenoviral DNA, wherein the adenoviral DNA comprises a therapeutic polynucleotide.
- 42. As a composition of matter, a liposome comprised of DOTAP, said liposome comprising:
adenoviral DNA, wherein the adenoviral DNA comprises a linear form; and a therapeutic polynucleotide.
- 43. The composition of claim 42, wherein said adenoviral DNA comprises said therapeutic polynucleotide.
- 44. The composition of claim 42, wherein the adenoviral DNA is comprised within the liposome.
- 45. The composition of claim 42, wherein the adenoviral DNA is not housed within an adenoviral particle.
- 46. A mixture of liposomes and adenoviral DNA, wherein the adenoviral DNA is housed within the liposomes, said mixture substantially lacking adenoviral DNA outside said liposomes.
- 47. The mixture of claim 46, wherein the adenoviral DNA comprises a therapeutic polynucleotide.
- 48. The mixture of claim 46, wherein the adenoviral DNA is not housed within an adenoviral particle.
Parent Case Info
[0001] The present invention claims priority to U.S. Provisional Patent Applications Serial No. 60/359,205, filed Feb. 22, 2002, and Ser. No. 60/383,246, filed May 24, 2002, both of which are incorporated by reference herein in their entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] U.S. Government funds pursuant to NIH Grant No. CA78792 were used for the present invention. The U.S. Government may have certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60359205 |
Feb 2002 |
US |
|
60383246 |
May 2002 |
US |